An Open-Label, Expanded Access Protocol of LAM-002A (Apilimod Dimeyslate Capsules), Administered to a Single Subject With C9ORF72-Associated Frontotemporal Dementia (FTD)
Latest Information Update: 06 Oct 2023
At a glance
- Drugs Apilimod dimesylate (Primary)
- Indications Frontotemporal dementia
- Focus Adverse reactions; Expanded access
- Sponsors OrphAI Therapeutics
Most Recent Events
- 08 Aug 2022 New trial record